Riccardo BragliaiOnctura Announces First Subject Dosed in Healthy Volunteer Study of Next Generation Autotaxin…* IOA-289 first ATX inhibitor to progress to clinic in oncology2 min read·Dec 17, 2021----
Riccardo BragliaTHE CANCER AND SUPPORTIVE CARE PRODUCTS AT HELSINNFor over 40 years, the Switzerland based pharmaceutical and biotechnology company Helsinn has been committed to providing cutting edge…1 min read·Nov 5, 2021----
Riccardo BragliaHelsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo®…Lugano, Switzerland — Shanghai, China, October 12, 2021 — Helsinn Group (“Helsinn”), a Swiss Biopharmaceutical Group with an innovative…4 min read·Oct 12, 2021----
Riccardo BragliaHelsinn Group and BridgeBio Pharma’s Affiliate QED Therapeutics Announce Health Canada Conditional…LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 — Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its…9 min read·Sep 29, 2021----
Riccardo BragliaArt Collecting — From Ancient Civilizations to Contemporary ArtPeople buy art to appreciate it and enhance their life and environment. Ancient Greek and Egyptian civilizations started collecting art…2 min read·Jul 30, 2021----
Riccardo BragliaSwiss-Italian Pharmaceutical Entrepreneur Riccardo BragliaThe chief executive officer and group vice chairman of the board of Helsinn Group in Lugano, Switzerland, Riccardo Braglia has spent 35…1 min read·Apr 7, 2021----
